LEAP-006: limits and potential of integrating anti-angiogenic agents into first-line multimodal therapy for non-squamous non-small cell lung cancer
Valentina Santo, Edoardo Garbo, Federica Pecci, Mihaela Aldea, Biagio Ricciuti, Eleonora Gariazzo · 2025
Read LEAP-006: limits and potential of integrating anti-angiogenic agents into first-line multimodal therapy for non-squamous non-small cell lung cancer by Valentina Santo, Edoardo Garbo, Federica Pecci, Mihaela Aldea, Biagio Ricciuti, Eleonora Gariazzo (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12780386.txt.
Description
Valentina Santo and five co-authors wrote a 2025 review of a trial called LEAP-006 in lung cancer. The trial tested first treatment for patients with a common form of the disease, non-squamous non-small cell lung cancer. Standard care now pairs immune drugs with standard drug treatment, yet a fair share of patients still do poorly.
The trial added a drug that blocks blood vessel growth in tumors. The hope was that cutting the tumor's blood supply would change its inner scene and let immune cells pour in. Groups with low scores on a key marker, or with no history of tobacco use, stood to gain most. The review weighs the limits and the promise of the mix. It asks which patients should get the extra drug and at what cost in side effects.
Catalog record
| CREATOR | Valentina Santo, Edoardo Garbo, Federica Pecci, Mihaela Aldea, Biagio Ricciuti, Eleonora Gariazzo |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |